Correlia Biosystems Status
The company raised venture funding from Pallasite Ventures on an undisclosed date. Prior to that, the company joined Y Combinator as part of its Winter 2018 Class on March 19, 2018 and received $120,000 in funding.
Developer of a streamlined assay platform designed to reduce the time and cost for quantifying proteins for proteomic and pharmaceutical applications. The company's platform provides multiplexing capabilities for large protein panels including cytokines and post-translational modifications with unparalleled speed and automation, enabling researchers to access large panel protein studies as well as reduces the cost and time to market for candidate drug compounds.
Year Founded
2013
Employees
5
General Information
-
Website
-
Business Status
Generating Revenue
-
Ownership Status
Privately Held (backing)
-
Financing Status
Venture Capital-Backed
Correlia Biosystems News and Updates
Y Combinator
Silicon Valley Bank | October 30, 2023
Correlia Biosystems Closes $7M Series A to Enable Product Launch
PR Newswire | November 20, 2020
Here are 16 more Bay Area startups who pitched at Monday's ...
The Business Journals | March 20, 2018
Correlia Biosystems's Verticals
Correlia Biosystems Primary Industry Sector / Group / Code
Correlia Biosystems's Trends
Correlia Biosystems Metrics
Growth Rate
Majestic Referring Domains
Headquarters
-
HQ Address Line 1626 Bancroft Way
-
HQ Address Line 2Suite A
-
HQ CityBerkeley
-
HQ State/ProvinceCalifornia
-
HQ Post Code94710
-
HQ CountryUnited States
Correlia Biosystems's Keywords
mood_badFeed is empty.
Add a review